Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis

JACC Heart Failure(2021)10.1016/j.jchf.2021.06.007Source: DataRank Database

Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis is a research paper published in JACC Heart Failure (2021). On theSindex it has a DataRank of 0. It has been cited 46 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

46 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 2.15)OA: closedTopics (28)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Mazen Hanna ORCID,Sanjiv J. Shah ORCID,Wael A. Jaber ORCID,John A. Spertus ORCID,Brett W. Sperry ORCID

Live enrichment

PubMed:34509404 OpenAlex:https://openalex.org/W3197703209

National Institutes of Health

Grant: R01 HL107577

National Institutes of Health

Grant: R01 HL127028

National Institutes of Health

Grant: R01 HL140731

National Institutes of Health

Grant: R01 HL149423

Actelion Pharmaceuticals

United Therapeutics Corporation

AstraZeneca

Pfizer

Abbott Laboratories

FWCI

2.15

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S2213177921003206?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213177921003206?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jchf.2021.06.007

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34509404

Fields of Study

Amyloidosis: Diagnosis, Treatment, OutcomesHeart Failure Treatment and ManagementHormonal Regulation and Hypertension

MeSH Terms

Mineralocorticoid Receptor AntagonistsAmyloidosisEchocardiographyHeart FailureHumansPhenotypeSpironolactoneStroke VolumeTreatment Outcome

Keywords

MedicineSpironolactoneInternal medicineCardiologyCardiac amyloidosisHeart failureClinical endpointCohortPopulationEjection fractionHeart failure with preserved ejection fractionRandomized controlled trialAngiotensinAldosteroneDiastolic Heart FailureMineralocorticoid Receptor Antagonist

Sustainable Development Goals

SDG 0: Good health and well-being

Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis

FAIR Checklist

Authors (5)

Funding (9 grants)

Impact

Open Access

Topics